In this context, Tissino et al. reported a relationship between ibrutinib exposure and impaired CLL cell adhesion on VCAM-1 substrates in vitro and a progressive reduction of constitutive VLA-4 activation during in vivo ibrutinib treatment (79). Here, VCAM1 is linked to B-cell chronic lymphocytic leukemia.